Compare · NVO vs PPCB
NVO vs PPCB
Side-by-side comparison of Novo Nordisk A/S (NVO) and Propanc Biopharma Inc. (PPCB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PPCB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 76518.9x PPCB ($2.4M).
- Over the past year, NVO is down 34.2% and PPCB is down 96.3% - NVO leads by 62.0 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 2 for PPCB).
- NVO has more recent analyst coverage (25 ratings vs 0 for PPCB).
- Company
- Novo Nordisk A/S
- Propanc Biopharma Inc.
- Price
- $41.18+6.93%
- $0.11-2.28%
- Market cap
- $183.82B
- $2.4M
- 1M return
- +13.32%
- -3.13%
- 1Y return
- -34.24%
- -96.27%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 2
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest PPCB
- SEC Form EFFECT filed by Propanc Biopharma Inc.
- SEC Form S-1 filed by Propanc Biopharma Inc.
- SEC Form DEF 14C filed by Propanc Biopharma Inc.
- Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
- SEC Form PRE 14C filed by Propanc Biopharma Inc.
- SEC Form PRE 14A filed by Propanc Biopharma Inc.
- Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
- Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
- SEC Form 424B3 filed by Propanc Biopharma Inc.
- Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models